Literature DB >> 3856477

Evolution of methotrexate resistance of human acute lymphoblastic leukemia cells in vitro.

T Ohnuma, R J Lo, K J Scanlon, B A Kamen, T Ohnoshi, S R Wolman, J F Holland.   

Abstract

A human acute lymphoblastic T-cell line, MOLT-3, was fed with Roswell Park Memorial Institute Medium 1640 supplemented with 10% fetal bovine serum and antibiotics which contained increasing concentrations of methotrexate (MTX). The development of drug resistance was associated initially with progressive decrease in MTX transport. When the cells became 200-fold resistant, a rise in the dihydrofolate reductase was noted which was short-lived in the absence of the drug. A 10,000-fold increase in MTX resistance was accompanied, in addition to further decrease in MTX transport, by a 10-fold increase in the dihydrofolate reductase activity. While the purely transport-related resistant cell lines had a collateral sensitivity to lipid-soluble antifols, the sublines which had both transport- and enzyme-related MTX resistance contained a subpopulation highly resistant to these antifols. Chromosome analysis of the subline with increased dihydrofolate reductase activity showed an expanded abnormally banded region in chromosome 5.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3856477

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

Review 1.  Resistance to cytostatic drugs at the cellular level.

Authors:  C P Vendrik; J J Bergers; W H De Jong; P A Steerenberg
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Isolation and characterization of a dihydrofolate reductase gene mutation in methotrexate-resistant Drosophila cells.

Authors:  H Hao; M G Tyshenko; V K Walker
Journal:  Gene Expr       Date:  1996

3.  A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717).

Authors:  Y Takemura; T Ohnuma; H Miyachi; S Sekiguchi
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

4.  Amplification of the thymidylate synthase gene in an N10-propargyl-5,8-dideazafolic-acid-resistant human leukemia, MOLT-3 cell line developed in pteroylglutamic acid, but not in leucovorin.

Authors:  H Miyachi; Y Takemura; H Kobayashi; Y Ando
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

5.  Methotrexate administered by 6-h and 24-h infusion: a pharmacokinetic comparison.

Authors:  J D Borsi; D Schuler; P J Moe
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

Review 6.  Biological and biochemical properties of new anticancer folate antagonists.

Authors:  D W Fry; R C Jackson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

7.  Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.

Authors:  Y Takemura; W Gibson; R Kimbell; H Kobayashi; H Miyachi; A L Jackman
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

8.  Biological activity and intracellular metabolism of ZD1694 in human leukemia cell lines with different resistance mechanisms to antifolate drugs.

Authors:  Y Takemura; H Kobayashi; H Miyachi; W Gibson; R Kimbell; A L Jackman
Journal:  Jpn J Cancer Res       Date:  1996-07

9.  Differential alterations of dihydrofolate reductase gene in human leukemia cell lines made resistant to various folate analogues.

Authors:  H Miyachi; Y Takemura; H Kobayashi; K Ando; Y Ando
Journal:  Jpn J Cancer Res       Date:  1993-01

10.  Cytotoxicity of trimetrexate against antifolate-resistant human T-cell leukemia cell lines developed in oxidized or reduced folate.

Authors:  H Miyachi; Y Takemura; H Kobayashi; Y Ando
Journal:  Jpn J Cancer Res       Date:  1997-09
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.